Clinical trials: Alteplase
Central Retinal Artery Occlusion
Early Reperfusion Therapy With Intravenous Thrombolysis for Recovery of VISION in Acute Central Retinal Artery Occlusion
Non-arteritic, thromboembolic central retinal artery occlusion (CRAO) is an acute neurovascular-ophthalmological emergency which leads to severe and permanent vision loss; no evidence-based therapy does exist.
- Trial name
- REVISION (NCT04965038)
- Testing
- Tenecteplase (until trial protocol V04: Alteplase)
- Where
- Germany
- Volunteers
- 127 people
- Sponsor
- University Hospital Tuebingen
Myocardial Infarction, Percutaneous Coronary Intervention
Adjunctive, Low-dose tPA in Primary PCI for STEMI
STRIVE will evaluate the use of adjunctive, low-dose intracoronary tissue plasminogen activator during primary percutaneous coronary intervention (PCI) for patients with ST elevation myocardial infarction (STEMI) in reducing the…
- Trial name
- STRIVE (NCT03335839)
- Testing
- tissue plasminogen activator, Saline
- Where
- 3 sites in Canada
- Volunteers
- 210 people
- Sponsor
- Population Health Research Institute
Acute Pulmonary Embolism
Changes of Cardiopulmonary Function After Thrombolysis in Patients With Pulmonary Embolism
The investigators expect to enroll about 80-100 acute pulmonary embolism patients treated with thrombolysis in two hospitals. Dynamic changes of cardiopulmonary function after thrombolysis are detected to evaluate which…
- Trial name
- CCFATAPE (NCT04757129)
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Bin He
Stroke, Acute
Embolectomy in Acute SYlvian Thrombosis in Refractory or Ineligible Patients to ALteplase
This trial aims at comparing two strategies currently used to address acute ischemic stroke of the middle cerebral artery : medical treatment without endovascular treatment on the one hand, and medical treatment plus endovascular…
- Trial name
- EASY (NCT02216565)
- Testing
- Hospitalization in specialized neuro-vascular unit, Alteplase if patient is eligible, Supportive care
- Where
- 3 sites in France
- Volunteers
- 2 people
- Sponsor
- Fondation Ophtalmologique Adolphe de Rothschild
Acute Ischemic Stroke
Aureva Transcranial Ultrasound Device With tPA in Patients With Acute Ischemic Stroke
This is a randomized, placebo controlled, double-blind phase 3 clinical study to evaluate the efficacy and safety of transcranial ultrasound (TUS) using the Sonolysis Headframe as an adjunctive therapy to intravenous (IV) tissue…
- Trial name
- TRUST (NCT03519737)
- Testing
- tPA in combination with the Sonolysis Headframe (TUS)
- Where
- 2 sites in United States
- Volunteers
- 596 people
- Sponsor
- Cerevast Medical, Inc.
Ischemic Stroke, Acute
Intra-arterial Recombinant Human TNK Tissue-type Plasminogen Activator (rhTNK-tPA) Thrombolysis for Acute Large Vascular Occlusion After Successful Mechanical Thrombectomy Recanalization
The goal of this clinical trial is to evaluate whether intra-arterial (IA) rhTNK-tPA thrombolysis can improve neurological outcomes in acute large vessel occlusion patients after successful mechanical thrombectomy (MT)…
- Trial name
- ANGEL-TNK (NCT05624190)
- Testing
- Recombinant Human tenecteplase Tissue-type Plasminogen Activator (rhTNK-tPA), Best Medical Management
- Where
- China
- Volunteers
- 256 people
- Sponsor
- Beijing Tiantan Hospital
Pulmonary Embolism, Acute Pulmonary Embolism
Submassive and Massive Pulmonary Embolism Treatment With Ultrasound Accelerated Thrombolysis Therapy
The purpose of this study is to determine if the EKOS EkoSonic® Endovascular Device when used in conjunction with recombinant tissue plasminogen activator (t-PA) as a treatment for acute PE will decrease the ratio of right…
- Conditions
- Pulmonary Embolism, Acute Pulmonary Embolism, Sub-massive Pulmonary Embolism, Massive Pulmonary Embolism
- Trial name
- SEATTLE II (NCT01513759)
- Testing
- recombinant tissue plasminogen activator, EKOS EkoSonic Endovascular System
- Where
- 22 sites in United States
- Volunteers
- 150 people
- Sponsor
- Boston Scientific Corporation
Argatroban, Rt-PA
Argatroban Plus r-tPA for Posterior Circulation Infarction（AR-PCI）
Acute ischemic stroke (AIS) is the most common type of stroke, which has high rate of morbidity, mortality and disability. A large number of studies have confirmed that the thrombolytic therapy can effectively open blood vessels…
- Trial name
- NCT03506009
- Testing
- Argatroban combined with rt-PA, rt-PA
- Where
- China
- Volunteers
- 3 people
- Sponsor
- Hui-Sheng Chen
Sepsis-induced Coagulopathy
The Diagnostic and Prognostic Value of TAT, PIC, tPAI·C and TM in Sepsis-induced Coagulopathy
In order to evaluate the diagnostic and prognostic value of thrombin-antithrombin complex（TAT）, α2-plasmin inhibitor-plasmin complex（PIC）, tissue plasminogen activator-inhibitor complex（tPAI·C） and thrombomodulin（TM） in…
- Trial name
- NCT06379126
- Testing
- Test thrombin-antithrombin complex（TAT）, α2-plasmin inhibitor-plasmin complex（PIC）, tissue plasminogen activator-inhibitor complex（tPAI·C） and thrombomodulin（TM）
- Volunteers
- 210 people
- Sponsor
- The First Hospital of Jilin University
Thrombosis
Low-Dose rtPA to Treat Blood Clots in Major Arm or Neck Veins
This study will test the effectiveness of low-dose recombinant tissue plasminogen activator (rtPA, or alteplase) in dissolving blood clots in major arm or neck veins.
- Trial name
- NCT00055159
- Testing
- Pulse-sprayed injection of recombinant tissue plasminogen activator (rtPA)
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Intracerebral Hemorrhage, ICH - Intracerebral Hemorrhage
Synergistic Minimally Invasive Surgery and Deferoxamine in ICH
This is a multicenter, randomized, open-label trial designed to evaluate the safety, feasibility, and efficacy of combining minimally invasive surgery (MIS) with intravenous deferoxamine (DFX) for the treatment of spontaneous…
- Trial name
- SMAD (NCT07162363)
- Testing
- Minimally Invasive surgery (MIS), Deferoxamine, Standard Medical Care (SMD)
- Where
- United States
- Volunteers
- 240 people
- Sponsor
- University of Illinois at Chicago
Acute Ischemic Stroke
A Multicenter, Three-Arm, Open-Label, Endpoint-Blinded Randomized Controlled Trial to Evaluate the Optimal Duration of Early Tirofiban After Intravenous Thrombolysis in Acute Ischemic Stroke
Acute ischemic stroke is a leading cause of disability and mortality among dults in China. Although intravenous thrombolysis serves as first-line reperfusion therapy, nearly half of patients fail to achieve vascular…
- Trial name
- INSTANT-2 (NCT07842185)
- Testing
- Tirofiban Injection, No Interventions
- Where
- 10 sites in China
- Volunteers
- 1,482 people
- Sponsor
- Xinqiao Hospital of Chongqing
Ischemic Stroke
Study for the Use of Alteplase in Patients Who Awaken With Stroke
This is a pilot study of thrombolytic therapy in patients with ischemic stroke who present with stroke symptoms upon awakening.
- Trial name
- AWOKE (NCT01150266)
- Testing
- Alteplase (tPA)
- Where
- United States
- Sponsor
- University of California, San Diego
Pleural Empyema
Intrapleural DNase and Tissue Plasminogen Activator in Pediatric Empyema (DTPA Trial)
Bacterial pneumonia can be complicated by the development of excess fluid and pus (pleural empyema) around the lungs in children. The incidence of pleural empyema in children has increased significantly in the last 10 years.
- Trial name
- NCT01717742
- Testing
- TPA (Tissue Plasminogen Activator), DNase
- Where
- 6 sites in Canada
- Volunteers
- 97 people
- Sponsor
- The Hospital for Sick Children
Heart Transplantation
Brachial Artery t-PA Release in Heart Transplant Recipients
Bradykinin stimulates t-PA release from intact vessels, but not from endothelial cells in culture. It has been proposed that the nerves of blood vessels are the source of bradykinin stimulated t-PA release.
- Trial name
- P1A3C (NCT00780637)
- Testing
- Bradykinin
- Where
- United States
- Sponsor
- Vanderbilt University
Acute Ischemic Stroke
A Study to Evaluate the Effects of YM872 on Brain Function and Disability When Administered in Combination With Alteplase (Tissue Plasminogen Activator)
The purpose of this study is to determine if YM872 in combination with t-PA can reduce disability and brain damage from stroke. YM872 or placebo will be given as a continuous intravenous (iv) infusion for 24 hours.
- Trial name
- NCT00044057
- Testing
- YM872 (zonampanel), t-PA (alteplase)
- Where
- 118 sites in United States, Austria and 3 more
- Sponsor
- Astellas Pharma Inc
Ischemic Stroke
Randomized Controlled Trial of Argatroban With Tissue Plasminogen Activator (tPA) for Acute Stroke
Randomized controlled clinical trial to estimate overall treatment benefit (improvement in disability) among stroke patients treated with rt-PA who are randomized to also receive either low-dose Argatroban, high-dose Argatroban…
- Trial name
- ARTSS-2 (NCT01464788)
- Testing
- Low Dose Argatroban, High Dose Argatroban, rt-PA (alteplase)
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- Andrew D. Barreto, MD
Empyema, Pleural Effusion
Alteplase for Treatment of Empyema and Complicated Parapneumonic Effusion
The purpose of this study is to assess the benefit to patients with empyema or complicated parapneumonic effusion (CPE) using a daily versus twice daily Alteplase regimen of two different dose strategies compared with saline…
- Trial name
- NCT00103766
- Testing
- Alteplase
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- O'Brien, Jeana D., MD, FACP, FCCP
Thrombolysed
To Compare the Efficacy & Safety of Ultra-Slow (24 hr) Low Dose (25 mg) Infusion of Alteplase Over Slow (24hr) Infusion of Streptokinase in Mechanical Prosthetic Valve Thrombosis
Annual incidence of PVT for mechanical valves is 0.3 - 1.3% patient-yrs. First postoperative year is marked by a 24% incidence of thrombosis.
- Trial name
- PHVT (NCT07360717)
- Testing
- Alteplase, streptokinase
- Where
- India
- Volunteers
- 100 people
- Sponsor
- U. N. Mehta Institute of Cardiology and Research Center
Post-stroke Seizure, Post-stroke Epilepsy
Post-stroke Seizure and Epilepsy Following Thrombolytic Therapy
This retrospective cohort study was conducted by reviewing the records of consecutive patients referred to Bu Ali Sina Hospital from 2016 to 2023, who were hospitalized with a diagnosis of ischemic stroke.
- Conditions
- Post-stroke Seizure, Post-stroke Epilepsy, Thrombolytic (t-PA) Treatment
- Trial name
- NCT06812000
- Where
- Iran
- Volunteers
- 199 people
- Sponsor
- Mazandaran University of Medical Sciences